Form 4: Amgen Director Tyler Jacks Acquires 665 Shares

Amgen Inc. director Tyler Jacks acquired 665 shares of common stock through the immediate vesting of Restricted Stock Units.

Summary

• Director Tyler Jacks acquired 665 shares of Amgen Inc. common stock on May 19, 2026.
• The acquisition resulted from the immediate vesting of Restricted Stock Units (RSUs) granted under the 2009 Director Incentive Program.
• Following this transaction, the reporting person holds a total of 18,284 shares of common stock.
• The transaction was executed at a price of $0 per share as part of director compensation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial outlook.

Positives

• Director alignment with shareholder interests is maintained through equity-based compensation.
• The reporting person increased their direct beneficial ownership of company stock.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that this filing represents standard corporate governance practice where directors receive equity compensation to align their interests with long-term shareholder value, common among large-cap biotechnology firms.

Comparison to Industry Standards

• The use of RSU grants for board compensation is consistent with standard practices at major biopharmaceutical companies like Gilead Sciences, Biogen, and Regeneron.
• Immediate vesting of director equity is a standard mechanism for board compensation in the S&P 500.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard director compensation event.

Next Steps

• No future actions or milestones mentioned.

Key Dates

Keywords

Amgen, AMGN, Form 4, Insider Trading, Director Compensation, Equity Incentive Plan